Post-earnings recap
Reported
Tue, Aug 4, 2026
EPS actual
$4.02
EPS est.
$4.01
EPS surprise
+0.20%
1-day move
-2.43%
DaVita Inc. reported an EPS that beat expectations slightly, but the stock fell by 2.43% following the earnings release. The lack of revenue data and management commentary may have contributed to investor uncertainty, leading to the stock's decline.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $4.02 | N/A | +0.20% |
| Revenue | N/A | N/A | N/A |
No transcript is on record, and the analysis is based on numerical results only.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
DaVita Inc. is a leading provider of kidney care services, operating dialysis centers across the United States. As a key player in the health care sector, its performance is closely tied to trends in chronic disease management and health care spending.
Last quarter
In Q1 2026, DaVita reported an EPS of $2.87, exceeding expectations by 19%. The stock reacted positively, gaining nearly 2% the following day.
Management promises and guidance
EPS beat streak
3Q
EPS beat rate
75%
Avg EPS surprise
+2.47%
Avg 1-day reaction
+0.47%
Analysts are cautiously optimistic about DaVita's upcoming earnings, expecting solid performance driven by patient growth and operational improvements.
Bull case
If DaVita exceeds EPS expectations and shows strong patient growth, it could signal robust demand for its services, leading to a significant stock price increase.
Bear case
Conversely, if the company reports lower-than-expected patient growth or operational challenges, it could raise concerns about future profitability, negatively impacting the stock.
Key metrics to watch
EPS
$2.75Earnings per share is a critical indicator of profitability and financial health, reflecting how much profit is allocated to each share of stock.
Patient Growth
2% YoY growthTracking the number of patients treated is essential for understanding demand for services and potential revenue growth.
The print will turn on these.
Q1
What is the expected patient growth rate for Q2 2026?
Patient growth is crucial for revenue generation, and any deviation from expectations could significantly impact investor sentiment.
Q2
How is DaVita managing operational costs in light of rising health care expenses?
Understanding cost management strategies will be key to evaluating the company's profitability and sustainability.
Why consensus could be wrong
The Street may underestimate DaVita's ability to manage costs effectively while expanding its patient base, which could lead to better-than-expected margins.
Supporting evidence
DaVita has historically shown resilience in patient retention and growth, even in challenging environments.
Recent operational improvements may not be fully reflected in analyst expectations, leading to potential upside.
The options market is pricing a significant move, indicating that investors anticipate volatility that may not align with consensus views.
Key risk
If patient growth exceeds 3%, it could challenge the current bearish sentiment and shift expectations significantly.
Pre-commit to what would confirm each case.
This quarter's performance will hinge on DaVita's ability to manage costs while expanding its patient base in a competitive health care environment.
Bull confirmed if
Achieving an EPS of $2.75 or higher with patient growth exceeding 2% would confirm a strong bull case.
Bear confirmed if
An EPS below $2.50 or patient growth below 1% would validate the bear case.
What the market is pricing for the move.
Implied Move
±19.68%
Historical Avg
±1.7%
The options market is pricing in a significant potential move in either direction, suggesting heightened uncertainty around the earnings report.
Options are pricing ±19.7% while DVA has averaged ±1.7% over the last 8 prints — setup is pricing rich.
ATM IV
0.4%
30d HV
65.2%
Smart-money positioning from the most recent 13F filings.
Institutional
48.38%
of float
Insider
46.91%
of float
Holders
860
institutions
Top Holders· as of Jun 2026
Berkshire Hathaway, Inc
28,880,209 sh · $5.1B
45.27%
-4.0%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If DaVita beats expectations, history suggests the stock could rise around 1.5% the next day, confirming strong operational performance.
In line / cautious
An in-line report may lead to muted reactions as investors await further clarity on future growth strategies.
Miss
If the company misses expectations, the stock could drop by about 0.8%, reflecting investor disappointment.
The lines on the call that would change the story.
Revenue Growth
5% YoY increaseRevenue growth indicates the company's ability to expand its business and capture more market share in the health care services industry.
Blackrock Inc.
2,460,987 sh · $435.1M
3.86%
-11.1%
Vanguard Capital Management LLC
2,101,425 sh · $371.5M
3.29%
-3.6%
Morgan Stanley
1,601,710 sh · $283.2M
2.51%
-3.9%
Vanguard Portfolio Management LLC
1,377,914 sh · $243.6M
2.16%
-6.9%
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.